nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Intestinal obstruction—Varenicline—nicotine dependence	0.0379	0.0541	CcSEcCtD
Solifenacin—Dysphonia—Varenicline—nicotine dependence	0.0314	0.0448	CcSEcCtD
Solifenacin—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0286	0.0408	CcSEcCtD
Solifenacin—Hyperkalaemia—Varenicline—nicotine dependence	0.0254	0.0362	CcSEcCtD
Solifenacin—Dry eye—Varenicline—nicotine dependence	0.0239	0.034	CcSEcCtD
Solifenacin—Atrial fibrillation—Varenicline—nicotine dependence	0.0198	0.0282	CcSEcCtD
Solifenacin—Urinary retention—Varenicline—nicotine dependence	0.0178	0.0254	CcSEcCtD
Solifenacin—Liver function test abnormal—Varenicline—nicotine dependence	0.0173	0.0247	CcSEcCtD
Solifenacin—Dry skin—Varenicline—nicotine dependence	0.0172	0.0245	CcSEcCtD
Solifenacin—Abdominal pain upper—Varenicline—nicotine dependence	0.0171	0.0244	CcSEcCtD
Solifenacin—Infestation NOS—Varenicline—nicotine dependence	0.0145	0.0206	CcSEcCtD
Solifenacin—Infestation—Varenicline—nicotine dependence	0.0145	0.0206	CcSEcCtD
Solifenacin—Depression—Varenicline—nicotine dependence	0.0144	0.0206	CcSEcCtD
Solifenacin—Hepatobiliary disease—Varenicline—nicotine dependence	0.0137	0.0195	CcSEcCtD
Solifenacin—Hallucination—Varenicline—nicotine dependence	0.0129	0.0184	CcSEcCtD
Solifenacin—Urinary tract disorder—Varenicline—nicotine dependence	0.0128	0.0183	CcSEcCtD
Solifenacin—Oedema peripheral—Varenicline—nicotine dependence	0.0128	0.0182	CcSEcCtD
Solifenacin—Connective tissue disorder—Varenicline—nicotine dependence	0.0128	0.0182	CcSEcCtD
Solifenacin—Urethral disorder—Varenicline—nicotine dependence	0.0127	0.0181	CcSEcCtD
Solifenacin—Erythema multiforme—Varenicline—nicotine dependence	0.0123	0.0175	CcSEcCtD
Solifenacin—Eye disorder—Varenicline—nicotine dependence	0.0121	0.0173	CcSEcCtD
Solifenacin—Cardiac disorder—Varenicline—nicotine dependence	0.012	0.0172	CcSEcCtD
Solifenacin—Angiopathy—Varenicline—nicotine dependence	0.0118	0.0168	CcSEcCtD
Solifenacin—Immune system disorder—Varenicline—nicotine dependence	0.0117	0.0167	CcSEcCtD
Solifenacin—Mediastinal disorder—Varenicline—nicotine dependence	0.0117	0.0167	CcSEcCtD
Solifenacin—Mental disorder—Varenicline—nicotine dependence	0.0114	0.0162	CcSEcCtD
Solifenacin—Malnutrition—Varenicline—nicotine dependence	0.0113	0.0161	CcSEcCtD
Solifenacin—Dysgeusia—Varenicline—nicotine dependence	0.0111	0.0158	CcSEcCtD
Solifenacin—Vision blurred—Varenicline—nicotine dependence	0.0107	0.0152	CcSEcCtD
Solifenacin—Angioedema—Varenicline—nicotine dependence	0.0103	0.0147	CcSEcCtD
Solifenacin—Palpitations—Varenicline—nicotine dependence	0.00999	0.0142	CcSEcCtD
Solifenacin—Cough—Varenicline—nicotine dependence	0.00986	0.0141	CcSEcCtD
Solifenacin—Hypertension—Varenicline—nicotine dependence	0.00976	0.0139	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00956	0.0136	CcSEcCtD
Solifenacin—Dry mouth—Varenicline—nicotine dependence	0.00941	0.0134	CcSEcCtD
Solifenacin—CHRM4—Monoamine GPCRs—DRD2—nicotine dependence	0.00922	0.0309	CbGpPWpGaD
Solifenacin—Infection—Varenicline—nicotine dependence	0.00916	0.0131	CcSEcCtD
Solifenacin—Nervous system disorder—Varenicline—nicotine dependence	0.00905	0.0129	CcSEcCtD
Solifenacin—Tachycardia—Varenicline—nicotine dependence	0.009	0.0128	CcSEcCtD
Solifenacin—Skin disorder—Varenicline—nicotine dependence	0.00896	0.0128	CcSEcCtD
Solifenacin—CHRM5—Monoamine GPCRs—DRD2—nicotine dependence	0.00883	0.0296	CbGpPWpGaD
Solifenacin—Somnolence—Varenicline—nicotine dependence	0.0082	0.0117	CcSEcCtD
Solifenacin—Dyspepsia—Varenicline—nicotine dependence	0.00812	0.0116	CcSEcCtD
Solifenacin—Decreased appetite—Varenicline—nicotine dependence	0.00802	0.0114	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00796	0.0114	CcSEcCtD
Solifenacin—Fatigue—Varenicline—nicotine dependence	0.00795	0.0113	CcSEcCtD
Solifenacin—Constipation—Varenicline—nicotine dependence	0.00789	0.0112	CcSEcCtD
Solifenacin—CHRM4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00775	0.026	CbGpPWpGaD
Solifenacin—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00765	0.0256	CbGpPWpGaD
Solifenacin—Feeling abnormal—Varenicline—nicotine dependence	0.0076	0.0108	CcSEcCtD
Solifenacin—Gastrointestinal pain—Varenicline—nicotine dependence	0.00754	0.0108	CcSEcCtD
Solifenacin—CHRM5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00742	0.0249	CbGpPWpGaD
Solifenacin—Urticaria—Varenicline—nicotine dependence	0.00733	0.0104	CcSEcCtD
Solifenacin—Abdominal pain—Varenicline—nicotine dependence	0.00729	0.0104	CcSEcCtD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00711	0.0238	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00681	0.0228	CbGpPWpGaD
Solifenacin—Hypersensitivity—Varenicline—nicotine dependence	0.0068	0.00969	CcSEcCtD
Solifenacin—Asthenia—Varenicline—nicotine dependence	0.00662	0.00943	CcSEcCtD
Solifenacin—Pruritus—Varenicline—nicotine dependence	0.00653	0.0093	CcSEcCtD
Solifenacin—CHRM4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00629	0.0211	CbGpPWpGaD
Solifenacin—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.00622	0.0208	CbGpPWpGaD
Solifenacin—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.0062	0.0208	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—DRD2—nicotine dependence	0.00614	0.0206	CbGpPWpGaD
Solifenacin—Dizziness—Varenicline—nicotine dependence	0.0061	0.0087	CcSEcCtD
Solifenacin—Vomiting—Varenicline—nicotine dependence	0.00586	0.00836	CcSEcCtD
Solifenacin—Rash—Varenicline—nicotine dependence	0.00582	0.00829	CcSEcCtD
Solifenacin—Dermatitis—Varenicline—nicotine dependence	0.00581	0.00828	CcSEcCtD
Solifenacin—Headache—Varenicline—nicotine dependence	0.00578	0.00824	CcSEcCtD
Solifenacin—Nausea—Varenicline—nicotine dependence	0.00548	0.00781	CcSEcCtD
Solifenacin—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00523	0.0175	CbGpPWpGaD
Solifenacin—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00521	0.0174	CbGpPWpGaD
Solifenacin—CHRM2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00516	0.0173	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00479	0.0161	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00478	0.016	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00473	0.0158	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00442	0.0148	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00424	0.0142	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00424	0.0142	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00419	0.014	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00406	0.0136	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00381	0.0128	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00365	0.0122	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00359	0.012	CbGpPWpGaD
Solifenacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00318	0.0106	CbGpPWpGaD
Solifenacin—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00313	0.0105	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00298	0.00999	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00297	0.00996	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00294	0.00986	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00286	0.00958	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00285	0.00955	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00282	0.00945	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00265	0.00888	CbGpPWpGaD
Solifenacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00257	0.00862	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00257	0.0086	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00256	0.00857	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00254	0.00849	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00246	0.00824	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.0024	0.00802	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00236	0.00789	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00218	0.00729	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00215	0.00721	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00211	0.00706	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00206	0.0069	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00202	0.00676	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00198	0.00664	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—TAS2R16—nicotine dependence	0.00195	0.00655	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—DRD2—nicotine dependence	0.00192	0.00642	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—TAS2R16—nicotine dependence	0.00187	0.00627	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00178	0.00596	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00177	0.00591	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0017	0.00571	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—FGD1—nicotine dependence	0.00169	0.00566	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00166	0.00556	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00165	0.00554	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00164	0.00549	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—FGD1—nicotine dependence	0.00162	0.00542	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—OPRM1—nicotine dependence	0.00161	0.00538	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—OPRM1—nicotine dependence	0.00154	0.00515	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—FGD1—nicotine dependence	0.00153	0.00514	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00152	0.00511	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—FGD1—nicotine dependence	0.00147	0.00492	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.00147	0.00491	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00146	0.00489	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00145	0.00486	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00145	0.00486	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00145	0.00485	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00143	0.0048	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00142	0.00476	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00142	0.00475	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0014	0.0047	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00137	0.00458	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00135	0.00452	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00132	0.00441	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.00131	0.0044	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.0013	0.00436	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—DRD2—nicotine dependence	0.00128	0.00427	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0012	0.00402	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0012	0.00401	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00118	0.00397	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD2—nicotine dependence	0.00116	0.00389	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TAS2R16—nicotine dependence	0.00115	0.00387	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.00114	0.00381	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.00114	0.0038	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—FGD1—nicotine dependence	0.00112	0.00377	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD2—nicotine dependence	0.00111	0.00372	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TAS2R16—nicotine dependence	0.00111	0.0037	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.00108	0.00363	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.00108	0.00361	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—OPRM1—nicotine dependence	0.00107	0.00358	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.00103	0.00346	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.00103	0.00345	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00103	0.00344	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00102	0.00343	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—FGD1—nicotine dependence	0.00102	0.00342	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00101	0.0034	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—OPRM1—nicotine dependence	0.000908	0.00304	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—FGD1—nicotine dependence	0.000906	0.00303	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—OPRM1—nicotine dependence	0.000869	0.00291	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FGD1—nicotine dependence	0.000868	0.00291	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—OPRM1—nicotine dependence	0.000824	0.00276	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKR1B10—nicotine dependence	0.0008	0.00268	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—OPRM1—nicotine dependence	0.000789	0.00264	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.000783	0.00262	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.00078	0.00261	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.000779	0.00261	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.000776	0.0026	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD2—nicotine dependence	0.000773	0.00259	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TAS2R16—nicotine dependence	0.000769	0.00257	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKR1B10—nicotine dependence	0.000767	0.00257	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD2—nicotine dependence	0.000656	0.0022	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD2—nicotine dependence	0.000628	0.0021	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000612	0.00205	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.000611	0.00205	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.00061	0.00204	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.000609	0.00204	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000604	0.00202	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGD1—nicotine dependence	0.000603	0.00202	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.000598	0.002	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD2—nicotine dependence	0.000596	0.002	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD2—nicotine dependence	0.000571	0.00191	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—WASF2—nicotine dependence	0.000564	0.00189	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.000556	0.00186	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.000554	0.00186	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—OPRM1—nicotine dependence	0.000549	0.00184	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—WASF1—nicotine dependence	0.000541	0.00181	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—WASF2—nicotine dependence	0.00054	0.00181	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.00054	0.00181	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.000538	0.0018	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKR1B10—nicotine dependence	0.000533	0.00178	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—WASF1—nicotine dependence	0.000518	0.00173	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—OPRM1—nicotine dependence	0.000487	0.00163	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—OPRM1—nicotine dependence	0.000466	0.00156	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000442	0.00148	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000441	0.00148	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD2—nicotine dependence	0.000437	0.00146	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000402	0.00135	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.0004	0.00134	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD2—nicotine dependence	0.000397	0.00133	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.00038	0.00127	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000379	0.00127	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—WASF2—nicotine dependence	0.000375	0.00126	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000365	0.00122	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000363	0.00122	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—WASF1—nicotine dependence	0.00036	0.00121	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD2—nicotine dependence	0.000352	0.00118	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD2—nicotine dependence	0.000337	0.00113	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.000328	0.0011	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000327	0.0011	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—OPRM1—nicotine dependence	0.000324	0.00109	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD2—nicotine dependence	0.000237	0.000795	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD2—nicotine dependence	0.000237	0.000792	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD2—nicotine dependence	0.000234	0.000785	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000234	0.000783	CbGpPWpGaD
